secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2026-08-14T20:07:42+00:00
Accession:  0001213900-26-090055
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics Q2 2026 net loss $2.8M; closes Kira acquisition, $132M PIPE
-------------------------------------------------------------------------------

- Q2 2026 net loss $2.8M ($0.10/share); cash $7.3M at June 30, 2026.
- Closed all-stock acquisition of Kira Pharmaceuticals in July 2026.
- Raised $132M gross proceeds in PIPE co-led by Affinity and Ikarian.
- KP-104 Phase 2 interim data expected Q4 2026; briquilimab pre-BLA meeting Q1 2027.
- R&D expense $5.1M, G&A $4.1M for Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026090055/0001213900-26-090055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026090055/ea0302049-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-090055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer